PEAK6’s ARK Genomic Revolution ETF ARKG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$5.22M Buy
+96,300
New +$4.33M 0.01% 781
2022
Q2
– Sell
-75,500
Closed -$3.47M – 3927
2022
Q1
$3.47M Sell
75,500
-81,400
-52% -$3.88M 0.01% 1372
2021
Q4
$9.6M Sell
156,900
-416,000
-73% -$28.8M 0.02% 734
2021
Q3
$42.8M Sell
572,900
-1,876,700
-77% -$157M 0.1% 180
2021
Q2
$227M Sell
2,449,600
-1,439,600
-37% -$122M 0.54% 25
2021
Q1
$345M Buy
3,889,200
+3,727,700
+2,308% +$370M 0.84% 12
2020
Q4
$15.1M Buy
+161,500
New +$12.9M 0.03% 498

Other funds holding ARKG

PEAK6's ARKG Position: Q4 2025 in Review

PEAK6 sold out of ARK Genomic Revolution ETF (ARKG) in Q4 2025, closing a stake of 2,500 shares — an estimated $75K sold.

PEAK6 first reported a position in ARKG in Q4 2020 and held it in 6 quarters. The position peaked at $18.7M in Q1 2021. 244 funds tracked by Wall St. Rank hold ARKG as of Q4 2025.

  • PEAK6 reported no remaining ARK Genomic Revolution ETF position as of Q4 2025 after selling out during the quarter.
  • PEAK6 sold 2,500 ARK Genomic Revolution ETF shares in Q4 2025, an estimated $75K.
  • PEAK6 first reported a position in ARK Genomic Revolution ETF in Q4 2020 and held it in 6 quarters.
  • PEAK6's ARK Genomic Revolution ETF position peaked at $18.7M in Q1 2021.
  • 244 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q4 2025.

Based on PEAK6's 13F filing for Q4 2025, filed 13 Feb 2026.